Related Experiment Video
Updated: May 26, 2026

Osteoarthritis Pain Model Induced by Intra-Articular Injection of Mono-Iodoacetate in Rats
Published on: May 20, 2020
Vasoactive intestinal peptide advances chondrogenesis and modulates pathogenic mediators in human osteoarthritis
Karolina Tecza1, Cristina Rodríguez-Hernández1, Raúl Villanueva-Romero1,2
1Department of Cell Biology and Histology, Faculty of Biological Science, Complutense University of Madrid (ROR 02p0gd045), Madrid, 28040, Spain.
Abstract:
Current therapies for osteoarthritis (OA) focus on symptom management, rather than halting disease progression. Vasoactive intestinal peptide (VIP) has shown promising effects in musculoskeletal diseases, preserving joint integrity and modulating inflammation. This study investigates the potential of VIP to promote chondrogenic differentiation of human bone marrow mesenchymal stem cells (BM-hMSC) and to modulate inflammatory and cartilage extracellular matrix (ECM)-degrading mediators in human osteoarthritis articular chondrocytes (OA-hAC). BM-hMSC from healthy donors were cultured in 3D pellet sytems under chondrogenic conditions, with or without VIP, for up to 21 days. Chondrogenesis was evaluated through the expression of key markers (SOX9, COL2A1, and ACAN), hypertrophic markers (RUNX2, COL10A1, and MMP13), and glycosaminoglycans (GAG). VIP accelerated chondrogenic differentiation by inducing earlier mRNA and protein expression of chondrogenic markers and enhancing GAG production. In parallel, OA-hAC were cultured in 3D alginate microbeads and stimulated with fibronectin fragments (Fn-fs) in the presence and absence of VIP. We analysed the effects of VIP on cell proliferation, GAG production, and the modulation of complement components (C1R and C3) and matrix metalloproteinases (MMP1, MMP3, MMP9, and MMP13). VIP increased cell proliferation and GAG deposition while significantly reducing the production of complement component C1R and matrix metalloproteinases MMP1 and MMP13. Overall, these findings demonstrate that VIP advances chondrogenesis and exerts anti-inflammatory and anti-catabolic effects in 3D culture models. This study highlights the potential of VIP as a therapeutic agent and supports the combination of MSC-based approaches with VIP as a promising strategy to enhance cartilage regeneration and slow OA progression.
Related Concept Videos
Degenerative Disc Disease ll: Pathophysiology
Osteoclasts in Bone Remodeling
Chronic Pancreatitis II: Pathophysiology
Bone Formation by Endochondral Ossification
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Chronic Inflammation: Introduction